December 15th, 2015

Company Update (NYSE:BMY): High Stakes Intrigue In Hep C: Bristol-Myers Vs. Gilead

[at Seeking Alpha] – Gilead’s ( GILD ) reluctance to marry its Hep C drug Sovaldi with Bristol-Myers Squibb’s ( BMY ) daclatasvir forced Bristol to take evasive action. Bristol applied to the . . . → Read More: Company Update (NYSE:BMY): High Stakes Intrigue In Hep C: Bristol-Myers Vs. Gilead Similar Articles: Company Update (NASDAQ:GILD): High Stakes Intrigue In Hep C: Bristol-Myers Vs. Gilead Stock Update: Biogen Idec Inc. (NASDAQ:BIIB) – [video] Biogen CEO: More products, company is focused Boeing’s Double Top: Will the company continue to soar?

Bristol-Myers Squibb Company (NYSE:BMY) [at Seeking Alpha] – Gilead’s ( GILD ) reluctance to marry its Hep C drug Sovaldi with Bristol-Myers Squibb’s ( BMY ) daclatasvir forced Bristol to take evasive action. Bristol applied to the European Union for approval of …
Read more on … [visit site to read more]

Similar Articles:
  1. Company Update (NASDAQ:GILD): High Stakes Intrigue In Hep C: Bristol-Myers Vs. Gilead
  2. Stock Update: Biogen Idec Inc. (NASDAQ:BIIB) – [video] Biogen CEO: More products, company is focused
  3. Boeing’s Double Top: Will the company continue to soar?
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.